Assessment of human abuse potential of dasotraline compared to methylphenidate and placebo in recreational stimulant users

Drug and Alcohol Dependence
K S KoblanA Loebel

Abstract

The aim of this study was to evaluate the abuse potential of dasotraline, a novel dopamine and norepinephrine reuptake inhibitor with slow absorption (tmax, 10-12h) and elimination (t1/2=47-77 h) that is in development for the treatment of attention deficit hyperactivity disorder (ADHD). Recreational stimulant users (N=48) who had specific experience with cocaine, and who were able to distinguish methylphenidate (60 mg) versus placebo in a qualification session, were randomized, in a 6-period, double-blind, crossover design, to receive single doses of dasotraline 8 mg, 16 mg, and 36 mg, methylphenidate (MPH) 40 mg and 80 mg, and placebo. The primary endpoint was the Drug Liking Visual Analog Scale (VAS) score at the time of peak effect (Emax). There were no significant differences between the 3 doses of dasotraline and placebo on the drug liking VAS at Emax, and on most secondary endpoints. Both doses of MPH had significantly higher VAS-drug liking scores at Emax relative to both placebo (P<0.001 for all comparisons) and dasotraline 8 mg (P<0.001), 16 mg (P<0.001) and 36 mg (P<0.01). The increase in heart rate for MPH and dasotraline 36 mg showed a time-course that closely matched subject-rated measures such as Any Effects VAS....Continue Reading

References

Dec 1, 1991·British Journal of Addiction·M Farré, J Camí
Apr 28, 2001·Pharmacology, Biochemistry, and Behavior·S H KollinsC R Rush
May 22, 2003·Drug and Alcohol Dependence·Robert L Balster, George E Bigelow
May 22, 2003·Drug and Alcohol Dependence·Roland R GriffithsNancy A Ator
Nov 5, 2003·The American Journal of Psychiatry·Nora D Volkow, James M Swanson
Nov 20, 2003·Neuroscience and Biobehavioral Reviews·J M Swanson, N D Volkow
Feb 25, 2005·Experimental and Clinical Psychopharmacology·William W StoopsCraig R Rush
Mar 24, 2006·Drug and Alcohol Dependence·Shelley McColl, Edward M Sellers
Jan 5, 2008·Journal of the American Academy of Child and Adolescent Psychiatry·Timothy E WilensSteven Fusillo
Mar 11, 2008·Drug and Alcohol Dependence·Donald R JasinskiAlbert J Allen
Apr 3, 2008·The American Journal of Psychiatry·Salvatore MannuzzaFrancisco X Castellanos
Aug 20, 2010·Journal of Pain & Palliative Care Pharmacotherapy·UNKNOWN U.S. Food And Drug Administration
Oct 9, 2014·Postgraduate Medicine·David B Clemow, Daniel J Walker
May 8, 2015·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Kenneth S KoblanAntony Loebel

❮ Previous
Next ❯

Citations

Jan 30, 2019·Journal of Child and Adolescent Psychopharmacology·Robert L FindlingAntony Loebel
Mar 16, 2019·Expert Review of Neurotherapeutics·Pankhuree Vandana, Eugene Arnold
Aug 20, 2020·Psychopharmacology·Robert LewSeth C Hopkins
Mar 17, 2021·International Clinical Psychopharmacology·Lenard A AdlerAntony Loebel
Jul 29, 2021·Journal of Psychopharmacology·David J Heal, Sharon L Smith

❮ Previous
Next ❯

Related Concepts

Related Feeds

Attention Disorders

Attention is involved in all cognitive activities, and attention disorders are reported in patients with various neurological diseases. Here are the latest discoveries pertaining to attention disorders.